Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000375601

Medchemexpress LLC IK-930 | 2563892-44-2 | C19H19F3N4O2S | 25 MG
SDP

Catalog No. 5000375601
Encompass_Preferred

IK-930 (compound I-32) is identified as a potent and orally active TEAD inhibitor with an EC50 value of less than 0.1 μM. It has demonstrated good pharmacokinetic parameters in BALB/c mice when administered orally at 10 mg/kg, exhibiting a Cmax of 1088 ng/mL and an AUC 0-last of 4581 ng*h/mL. This product is intended for research use only and is not sold to patients.

  • Potent TEAD inhibitor: acts effectively against TEAD with a low EC50 value.
  • Orally active: can be administered orally.
  • Favorable pharmacokinetics: shows good drug absorption, distribution, metabolism, and excretion properties in vivo.
  • Research applications: suitable for studies related to TEAD inhibition and associated pathways.
  • Clinical trial involvement: being investigated for various solid tumors and conditions related to NF2 deficiency and YAP1/TAZ gene fusions.

Catalog No. 50-003-75601 Supplier Medchemexpress LLC Supplier No. 25MGHY153585
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

IK-930 (compound I-32) is identified as a potent and orally active TEAD inhibitor with an EC50 value of less than 0.1 μM. It has demonstrated good pharmacokinetic parameters in BALB/c mice when administered orally at 10 mg/kg, exhibiting a Cmax of 1088 ng/mL and an AUC 0-last of 4581 ng*h/mL. This product is intended for research use only and is not sold to patients.

  • Potent TEAD inhibitor: acts effectively against TEAD with a low EC50 value.
  • Orally active: can be administered orally.
  • Favorable pharmacokinetics: shows good drug absorption, distribution, metabolism, and excretion properties in vivo.
  • Research applications: suitable for studies related to TEAD inhibition and associated pathways.
  • Clinical trial involvement: being investigated for various solid tumors and conditions related to NF2 deficiency and YAP1/TAZ gene fusions.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.